MYCN and rhabdomyosarcoma: Thus, PTPRD is likely to have a tumor suppressor function in any type of cancer with MYCN amplification, including other pediatric cancers such as medulloblastoma and rhabdomyosarcoma, or in adult tumors that are dependent on high AURKA levels.